Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
HotCopper.com on MSN4d
Another win for Clarity at FDA as imaging agent fast-tracked for complex prostate cancerFor those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity ...
Last week, it licensed a series of fibroblast activation protein (FAP) targeting agents from iTheranostics that can be used to image and potentially ... called Lu-PSMA-617, which improved survival ...
The ligand is linked to a radioactive isotope molecule that can either be used to image the tumour ... to buy targeted radioligand therapy Lu-PSMA-617 from Endocyte, shortly after encouraging ...
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Wolfgang P.
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...
ISLAMABAD: The federal government has stepped up efforts to provide relief to the people of Pakistan during the holy month of Ramadan, issuing instructions to the provinces to provide sugar at ...
The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.
The ASX 200 pharmaceutical share notes that US FDA Fast Track designation is designed to facilitate the development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback